Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing innovative theranostic products that enhance treatment outcomes for cancer patients. Central to their approach is the proprietary SAR Technology platform, which utilizes copper isotopes for both diagnostic imaging and targeted therapy. This technology features a highly stable chelator that securely retains copper isotopes, preventing leakage into the body and ensuring that the radioisotopes can effectively target cancer cells. The platform is designed to address significant unmet needs in oncology, particularly for cancers such as neuroblastoma and prostate cancer, by providing high accuracy and precision in both diagnosis and treatment.

The company's lead product, SARTATE™, is a theranostic radiopharmaceutical that combines a well-characterized peptide with SAR Technology to target tumors expressing somatostatin receptor 2 (SSTR2). Clarity is also developing SAR-bisPSMA for prostate cancer and SAR-Bombesin for a range of cancers, showcasing the versatility of their SAR Technology. By leveraging the unique properties of copper isotopes, Clarity aims to improve the efficacy of cancer treatments while minimizing side effects, thereby advancing the field of radiopharmaceuticals and offering new hope for patients facing aggressive cancers.

Australia

Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products. It was founded in 2010 and is based in Australia. The company focuses on addressing the growing need for the use of radiopharmaceutical therapies in the treatment of serious diseases.

Clarity Pharmaceuticals

Company Details